Search
We aimed to explore whether newborns in high-risk areas have pre-existing pneumococcal-specific cellular immune responses that effects early acquisition.
To evaluate the effect on safety and coverage of earlier (18 m) scheduling of MMRV vaccine as the second dose of measles-containing vaccine in Australia.
We studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in children, 3-5 years of age, in community controls of a similar age.
Meningococcal serogroup B (MenB) strains are highly diverse. Breadth of immune response for the MenB vaccine, 4CMenB, administered at 0-2, 0-6, or 0-2-6 months, was demonstrated by endogenous complement-human serum bactericidal antibody (enc-hSBA) assay against an epidemiologically relevant panel of 110 MenB strains.
Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
The rising incidence of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup W in Western Australia, Australia, presents challenges for prevention. We assessed the effects of a quadrivalent meningococcal vaccination program using 2012-2020 IMD notification data.
Vaccination trials in high endemicity areas are needed to provide evidence and guidance on idea strategies to protect children in these areas against infections
The aim of our study was to characterize the activity of TNAP on TLR agonists and assess the concentrations of plasma ALP during late-onset sepsis in newborns.
This review aims to systematically identify and summarise the effects of different antifungal therapies in children with proven, probable or suspected...
Current infant vaccination against pertussis in North America and Australia requires three doses of vaccines including diphtheria, tetanus and acellular...